Literature DB >> 15013026

Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro.

Kristina Melkersson1.   

Abstract

This study was undertaken to examine the influence of conventional and atypical antipsychotics on insulin release in vitro, using isolated pancreatic islets and insulin-secreting INS-1 cells. The effect of the conventional antipsychotics haloperidol and zuclopenthixol, and the atypical agents clozapine and olanzapine in the concentration of 10(-6) M was investigated on basal and glucose-stimulated insulin release. Both clozapine and olanzapine increased basal insulin release, whereas zuclopenthixol inhibited glucose-stimulated release and haloperidol had no significant effect. In summary, clozapine and olanzapine, in contrast to conventional antipsychotics, increase basal insulin release. Interestingly, this stimulatory effect on insulin release in vitro may be supported by recent clinical findings, showing elevated insulin levels in patients being treated with clozapine or olanzapine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013026     DOI: 10.1016/S0924-977X(03)00072-5

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  23 in total

Review 1.  Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?

Authors:  Nathan Herrmann; Krista L Lanctôt
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 3.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 4.  Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

5.  Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

Authors:  Ren-Rong Wu; Jing-Ping Zhao; Zhe-Ning Liu; Jin-Guo Zhai; Xiao-Feng Guo; Wen-Bing Guo; Jing-Song Tang
Journal:  Psychopharmacology (Berl)       Date:  2006-04-07       Impact factor: 4.530

6.  Clozapine: Current perspective.

Authors:  Ram K Solanki; Paramjeet Singh; Mukesh K Swami
Journal:  Indian J Psychiatry       Date:  2007-10       Impact factor: 1.759

7.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

8.  Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro.

Authors:  Norman Simpson; Antonella Maffei; Matthew Freeby; Steven Burroughs; Zachary Freyberg; Jonathan Javitch; Rudolph L Leibel; Paul E Harris
Journal:  Mol Endocrinol       Date:  2012-08-21

Review 9.  Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism.

Authors:  K I Melkersson; M-L Dahl; A-L Hulting
Journal:  Psychopharmacology (Berl)       Date:  2004-06-25       Impact factor: 4.530

10.  A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.

Authors:  Shaohua Hu; Mingrong Yao; Bradley S Peterson; Dongrong Xu; Jianbo Hu; Jianliang Tang; Bing Fan; Zhengluan Liao; Tianyi Yuan; Yaling Li; Weiqing Yue; Ning Wei; Weihua Zhou; Manli Huang; Yi Xu
Journal:  Psychopharmacology (Berl)       Date:  2013-04-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.